Effect of omega-3 on blood pressure and serum lipids in continuous ambulatory peritoneal dialysis patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201501112417N16

Enrollment

Registered

2015-01-17

Start date

2012-04-28

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End Stage Renal Disease. End Stage Renal Disease

Interventions

Intervention 1: Cap Omega-3 1000mg 3capsule per day for 6 weeks manufactured by Zahravi company. Intervention 2: Cap placebofor 6 weeks manufactured by Zahravi company.

Treatment - Drugs

Placebo

Cap Omega-3 1000mg 3capsule per day for 6 weeks manufactured by Zahravi company

Cap placebofor 6 weeks manufactured by Zahravi company

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: inclusion criteria: Clinically stable patients without serious disease; continuous ambulatory peritoneal dialysis (CAPD) for at least 3 months; hypertension stage 1(according to JNC VII) or under treatment. Exclusion criteria: history of steatorrhea; malignancy; thrombocytopenia (PLT<100000/mm3); abnormal coagulation profile; need for anticoagulation therapy; psychosomatic disorders.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Triglyceride. Timepoint: Begining of the study, after 6 weeks. Method of measurement: mg/dL.;Cholesterol. Timepoint: Begining of the study, after 6 weeks. Method of measurement: mg/dL.;High density lipoprotein (HDL). Timepoint: Begining of the study, after 6 weeks. Method of measurement: mg/dL.;Systolic blood pressure. Timepoint: Begining of the study, after 6 weeks. Method of measurement: mmHg.;Diastolic blood pressure. Timepoint: Begining of the study, after 6 weeks. Method of measurement: mmHg.	—

Measure

Time frame

Triglyceride. Timepoint: Begining of the study, after 6 weeks. Method of measurement: mg/dL.;Cholesterol. Timepoint: Begining of the study, after 6 weeks. Method of measurement: mg/dL.;High density lipoprotein (HDL). Timepoint: Begining of the study, after 6 weeks. Method of measurement: mg/dL.;Systolic blood pressure. Timepoint: Begining of the study, after 6 weeks. Method of measurement: mmHg.;Diastolic blood pressure. Timepoint: Begining of the study, after 6 weeks. Method of measurement: mmHg.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Firouzeh Moeinzadeh

Isfahan University of Medical Sciences

moinzade@resident.mui.ac.ir+98 31 3628 3356

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026